Key Highlights

  • Loss per share was USD 0.76, against USD 0.65 a year earlier.
  • Net loss was USD 85.78 million, against USD 57.46 million a year earlier.
  • Research and development expenses were USD 69.51 million, against USD 49.19 million.
  • Cash and cash equivalents were USD 212.8 million at September 30.

Immunome (NASDAQ:IMNM) reported a third quarter 2026 loss per share of USD 0.76, compared with USD 0.65 in the third quarter of 2025. Net loss was USD 85.78 million, against USD 57.46 million in the prior-year quarter.

The loss from operations was USD 90.36 million, compared with USD 60.14 million. The company reported the figures in its quarterly filing for the period ended September 30, 2026.

Operating Expenses and Interest Income

Research and development expenses were USD 69.51 million, compared with USD 49.19 million. General and administrative expenses were USD 20.86 million, compared with USD 10.95 million. Total operating expenses were USD 90.36 million, against USD 60.14 million.

The filing says the increase in certain expense categories was due primarily to increased IND-enabling activities for product candidates and to higher personnel-related costs, including share-based compensation. Interest income was USD 4.58 million, compared with USD 2.68 million, reflecting higher cash, cash equivalent and marketable securities balances, partially offset by lower interest rates.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 212.75 million, compared with USD 142.49 million, and loss per share was USD 1.88, against USD 1.68. Total operating expenses were USD 227.83 million, against USD 158.19 million.

Research and development expenses for the nine months were USD 175.77 million, against USD 126.52 million, and general and administrative expenses were USD 52.06 million, against USD 31.68 million. Nine-month loss from operations was USD 227.83 million, against USD 151.25 million, and nine-month interest income was USD 15.08 million, against USD 8.76 million. Share-based compensation in the third quarter totaled USD 12.76 million, compared with USD 6.75 million.

Clinical Updates and Liquidity

In November 2026, the company announced that initial clinical data from its ongoing Phase 1 trial of IM-1021 would be presented in a poster at the 68th American Society of Hematology Annual Meeting. As of the abstract data cutoff of June 26, 2026, 35 patients had received IM-1021, including 25 with B-cell non-Hodgkin lymphoma, who had received a median of four prior lines of therapy, with prior T-cell redirecting therapy common.

The filing also states that Phase 3 data show varegacestat has a safety profile consistent with other Gamma secretase inhibitor therapies. As of September 30, 2026, the company had cash and cash equivalents of USD 212.8 million, marketable securities of USD 248.7 million and an accumulated Deficit of USD 940.9 million, and it believes these are sufficient to fund its operations for at least 12 months from the filing date.

Immunome Q3 2026 Earnings: Key Takeaways

Immunome reported a third quarter 2026 loss per share of USD 0.76 and a net loss of USD 85.78 million. Research and Development expenses were USD 69.51 million, and cash and cash equivalents and marketable securities were USD 212.8 million and USD 248.7 million.